237 related articles for article (PubMed ID: 33070945)
1. Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: A meta-analysis of randomized controlled trials.
Chang D; Gong M; Liu C; Zhang Q; Hu Z; Li Z
Med Clin (Barc); 2021 Nov; 157(9):418-426. PubMed ID: 33070945
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
3. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis.
Liu S; Gui C; Lu Z; Li H; Fu Z; Deng Y
Front Pediatr; 2021; 9():728010. PubMed ID: 34490171
[No Abstract] [Full Text] [Related]
5. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
7. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
[TBL] [Abstract][Full Text] [Related]
9. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
Ohyama R; Fujinaga S; Sakuraya K; Hirano D; Ito S
Clin Exp Nephrol; 2023 Oct; 27(10):865-872. PubMed ID: 37477752
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for nephrotic syndrome in children.
Iijima K; Sako M; Nozu K
Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of cyclosporine A in treatment of refractory nephrotic syndrome in children: a systematic review of randomized controlled trials].
Chen LZ; Jiang XY; Lu HY; Zhang QL; Mo Y
Zhonghua Er Ke Za Zhi; 2009 Dec; 47(12):898-903. PubMed ID: 20193140
[TBL] [Abstract][Full Text] [Related]
14. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy in adults with steroid-dependent nephrotic syndrome.
Zhong H; Li HY; Zhou T; Weng W
Arch Med Sci; 2023; 19(3):577-585. PubMed ID: 37313189
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial to compare safety and efficacy of mycophenolate vs. cyclosporine after rituximab in children with steroid-resistant nephrotic syndrome.
Assadi F; Mazaheri M; Sadeghi-Bodj S
Pharmacotherapy; 2022 Sep; 42(9):690-696. PubMed ID: 35869690
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital.
Bazargani B; Noparast Z; Khedmat L; Fahimi D; Esfahani ST; Moghtaderi M; Abbasi A; Afshin A; Mojtahedi SY
BMC Pediatr; 2022 Jan; 22(1):36. PubMed ID: 35022016
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.
Zhao Z; Liao G; Li Y; Zhou S; Zou H
Sci Rep; 2015 Feb; 5():8219. PubMed ID: 25645999
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
20. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Wong SC; Willis NS; Craig JC
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
